1 – 18 of 18
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell malignancies
(
- Contribution to journal › Article
-
Mark
Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity : A multi-center study
(
- Contribution to journal › Article
- 2019
-
Mark
HAX-1 overexpression in multiple myeloma is associated with poor survival
(
- Contribution to journal › Letter
-
Mark
First line therapy in chronic lymphocytic leukemia : a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
(
- Contribution to journal › Article
- 2016
-
Mark
New perspectives on complement mediated immunotherapy
(
- Contribution to journal › Scientific review
-
Mark
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia : Data from 95 consecutive patients treated in a compassionate use program. A study from the swedish chronic lymphocytic leukemia group
(
- Contribution to journal › Article
-
Mark
Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions
(
- Contribution to journal › Article
- 2015
-
Mark
Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation.
(
- Contribution to journal › Article
- 2014
-
Mark
Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas
(
- Contribution to journal › Article
- 2013
-
Mark
Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies.
(
- Contribution to journal › Scientific review
-
Mark
Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement.
(
- Contribution to journal › Article
- 2012
-
Mark
Upfront Autologuos Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01.
(
- Contribution to journal › Article
- 2010
-
Mark
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
(
- Contribution to journal › Article
-
Mark
Favorable Outcome In ALK Negative Anaplastic Large Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT) a Prospective Study by the Nordic Lymphoma Group (NLG T 01)
(
- Contribution to journal › Published meeting abstract
-
Mark
Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy Associated T Cell Lymphoma a Prospective Study by the Nordic Lymphoma Group (NLG T 01)
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.
(
- Contribution to journal › Article
-
Mark
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group
(
- Contribution to journal › Article
- 2007
-
Mark
Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations
(
- Contribution to journal › Article